{"doi":"10.1093/ije/dyad137","title":"Cohort Profile Update: Project Viva mothers","abstract":"Project Viva, a pre-birth cohort of 2128 mother-child pairs, was initiated in 1999–2002 in Massachusetts to examine the extent to which factors and events during pregnancy and the perinatal period affect health outcomes over a lifetime among women and their offspring. This updated cohort profile follows up women through mid-life. Two decades of continual follow-up enable us to evaluate women’s health across their reproductive years and health conditions that progress or emerge during mid-life. New measures in women include assessments of lifetime fertility, biomarkers of cardiometabolic health and bone turnover, plasma concentrations of per- and polyfluoroalkyl substance (PFAS) chemicals, dual-energy X-ray absorptiometry (DXA) scans for body composition and bone density, and menopause-related symptoms. We also collected 24-h dietary recalls, analysed DNA, assessed impact of the COVID pandemic, and measured multiple environmental chemicals and contextual factors based on residential addresses. A total of 843 women had any Mid-Life Visit data (2017–21; median age 51.1 years). At the start of the ongoing Women’s Health Visit 1 in April 2022, 1356 women (median age 54.0 years) were eligible to participate. Investigators interested in learning more about how to obtain Project Viva data can contact the Project Viva Principal Investigator Emily Oken at [[email protected]] or can get more information at [https://www.projectviva.org]. We established Project Viva to examine the extent to which events during the perinatal period may affect health outcomes over a lifetime. The cohort recruited pregnant women and follows women and their children over time. Research assistants recruited women at their initial prenatal visit (median 9.9 weeks’ gestation) April 1999–July 2002 from eight obstetric offices of Atrius Harvard Vanguard Medical Associates, a multispecialty group practice in suburban/urban Eastern Massachusetts.1 Women with a singleton pregnancy were eligible if they enrolled before 22 weeks’ gestation, planned to deliver at one of the two study hospitals and were able to answer questionnaires in English. We recruited 2622 women. After recruitment, we found 310 of them to be ineligible (moved out of study area, multiple gestation, miscarriage or stillbirth), leaving 2312 eligible women of whom 2100 were still enrolled at the time of delivery and had a live birth (Figure 1). Flow of Project Viva mothers’ involvement through the Mid-Life Visit. aCumulative number disenrolled from birth to visit. bIneligible for visit because no information on diet in pregnancy. We adapted Figure 1 from our original cohort profile1 Research assistants conducted mid-pregnancy in-person visits at the time of clinical glycaemic screening (median 27.9 weeks’ gestation) and delivery visits with mother and infant dyads in the hospital during the birth admission (median 39.7 weeks’ gestation). We obtained birth information on 2128 live-born singleton infants born to 2100 women (28 women enrolled with two separate pregnancies). We conducted additional in-person visits with mother and child dyads during infancy (median offspring age 6.2 months), early childhood (median 3.3 years), mid-childhood (median 7.7 years) and early adolescence (median 12.9 years), as described in our original cohort profile.1 Between visits, we administered annual mailed or online questionnaires. Since our original cohort profile,1 we completed additional research visits with women (‘Mid-Life Visit’, median age 51.1 years) and adolescents (‘Mid-Adolescent Visit’, median 17.5 years) over July 2017–August 2021. By ‘mid-life’, we mean the middle years of adulthood, roughly from ages 35 to 65.2 We also administered four additional questionnaire-only visits: the Year 19 Questionnaire (December 2019 to June 2022), the 2020 Questionnaire (May to September 2020), the 2021 Questionnaire (February to August 2021) and the 2022 Questionnaire (January to December 2022). Project Viva is now in a new ","journal":"International Journal of Epidemiology","year":2023,"id":327072,"datarank":0.49983067652628066,"base_score":3.332204510175204,"endowment":3.332204510175204,"self_citation_contribution":0.49983067652628066,"citation_network_contribution":0.0,"self_endowment_contribution":0.49983067652628066,"citer_contribution":0.0,"corpus_percentile":61.62295969675872,"corpus_rank":4961,"citation_count":27,"citer_count":4,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":true,"is_dataset_confidence":0.9337,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":336845,"name":"Izzuddin M. Aris","orcid":"0000-0002-9239-7476","position":1,"is_corresponding":false},{"id":448962,"name":"Karen M Switkowski","orcid":"0000-0001-8212-4354","position":2,"is_corresponding":false},{"id":278788,"name":"Jessica G. Young","orcid":"0000-0002-2758-6932","position":3,"is_corresponding":false},{"id":254531,"name":"Abby F. Fleisch","orcid":"0000-0002-2789-6412","position":4,"is_corresponding":false},{"id":317536,"name":"Tamarra James‐Todd","orcid":"0000-0003-3589-5169","position":5,"is_corresponding":false},{"id":317535,"name":"Ami R. Zota","orcid":"0000-0003-0710-354X","position":6,"is_corresponding":false},{"id":301092,"name":"Wei Perng","orcid":"0000-0001-8552-6850","position":7,"is_corresponding":false},{"id":230358,"name":"Marie‐France Hivert","orcid":"0000-0001-7752-2585","position":8,"is_corresponding":false},{"id":104574,"name":"Janet W. Rich‐Edwards","orcid":"0000-0001-5066-8808","position":9,"is_corresponding":false},{"id":1046721,"name":"Melissa Pérez Capotosto","orcid":"0000-0003-4453-7523","position":10,"is_corresponding":false},{"id":104573,"name":"Jorge E. Chavarro","orcid":"0000-0002-4436-9630","position":11,"is_corresponding":false},{"id":239883,"name":"Emily Oken","orcid":"0000-0003-2513-3339","position":12,"is_corresponding":false},{"id":254530,"name":"Sheryl L. Rifas‐Shiman","orcid":"0000-0003-0033-920X","position":0,"is_corresponding":true}],"reference_count":40,"raw_metadata":null,"created_at":"2026-07-19T01:08:37.840107Z","pmid":"37875013","pmcid":"PMC10749767","fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}